

Canadian **Retina** Society
Société canadienne de la **Rétine**

CRS 2016

Canada's Spotlight on Retina

March 3 - 6, 2016
Fairmont Tremblant



Program

This program was co-developed by the Canadian Retina Society and the Canadian Ophthalmological Society in order to achieve scientific integrity, objectivity and balance as per the RCPSC's accreditation guidelines.

www.cos-sco.ca/retina2016

CRS  SCR


Canadian Ophthalmological Society
Société canadienne d'ophtalmologie
EYE PHYSICIANS AND SURGEONS OF CANADA | MÉDECINS ET CHIRURGIENS OPHTHALMOLOGISTES DU CANADA

OUR SPONSORS

The Canadian Retina Society and the Canadian Ophthalmological Society gratefully acknowledge the participation of the following corporate sponsors, each of whom has provided an unrestricted educational grant in support of this meeting.

GOLD SPONSORS



Science For A Better Life

SILVER SPONSORS



BRONZE SPONSORS



FRIENDS



TABLE OF CONTENTS

Welcome	2
General Information	3
Guest Speakers	4
Dr. Mila Oh Memorial Lecture	6
Social Events	7
Scientific Program	7
Co-developed Symposia	9 / 11
Program at a Glance	22

We've Gone Mobile!

For detailed program information, scan the QR code or visit www.eventmobi.com/2016crs.

The free CRS meeting app can be viewed on any mobile device or computer.



WELCOME

Dear Delegates and Guest Speakers,

It is with great pleasure that we welcome you to the 2016 Canadian Retina Society (CRS) Meeting, “Canada’s Spotlight on Retina” – our annual opportunity to come together to learn from one another and to socialize, this year in beautiful Mont-Tremblant, Québec.

Together in Mont-Tremblant we join as part of the largest gathering of Canadian retina specialists for four days of scientific programming, networking opportunities and of course, fine dining and winter activities. This year’s program features renowned guest speakers from the United States and Canada. We have an excellent balance of both medical and surgical topics, and a schedule that will allow you to optimize your learning and adventure experiences at the #1 ski resort in Eastern North America.

We are pleased to be able to present the second year of data from our very own made-in-Canada “Canadian Practice and Trends (CAN-PAT) Survey.” We look forward to sharing these data with you, as it offers a fascinating glimpse into our daily choices in the clinic and the OR.


If you are a CRS member, we look forward to seeing you at the CRS Annual General Meeting on Thursday, March 3 from 17:30-19:00. The CRS Executive is busy all year supporting the needs of our members. This year’s agenda is particularly important as we elect the new leadership for our society.

We would like to thank the staff of the Canadian Ophthalmological Society for their attention to the many behind-the-scenes details that allow this meeting to run smoothly.

Finally, we could not produce and execute this meeting without the very generous support of our sponsors – we value our partnerships with each and every one. Please take the time to visit their displays.

Thank you for joining us in Mont-Tremblant – we wish you a wonderfully educational meeting, great skiing and safe travels!


Sincerely,



Jim Whelan, MD, FRCSC
President, CRS



Netan Choudhry, MD, FRCSC
Co-chair, CPD Director



Deepa Yoganathan, MD, FRCSC
Co-chair





GENERAL INFORMATION

REGISTRATION

The Registration Desk is located in the Tremblant Room at the Fairmont Tremblant.

Thursday, March 3	1530-1900	
Friday, March 4	0600-1030	1500-1830
Saturday, March 5	0600-1030	1500-1800
Sunday, March 6	0630-1030	

BREAKFAST AND REFRESHMENTS

All breakfasts and refreshment breaks will be served in Mali I/II. Light snacks and refreshments will be served in Mali III during the co-developed symposia.

SCIENTIFIC SESSIONS

All scientific sessions and the CRS Annual General Meeting will be held in Mali III.

SPEAKER INFORMATION

Guest speakers may visit the audio visual technician in Mali III for assistance with their presentations.

Note: All speakers are kindly asked to upload their final slides **at least one hour prior to their presentation time slot.**

CPD CREDITS

This meeting is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification (MOC) Program of The Royal College of Physicians and Surgeons of Canada (RCPSC), and approved by the Canadian Ophthalmological Society (COS). Physicians may claim a maximum of 15.5 credit hours.

The 2016 CRS meeting is co-developed with the CRS and the COS to achieve scientific integrity, objectivity and balance.

Through an agreement between the RCPSC and the American Medical Association (AMA), physicians

may convert MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert MOC credit to AMA credit can be found at [earning credit for participation in international activities](#).

Date	Hours	Attended
Thursday, March 3	1.25	
Friday, March 4	6	
Saturday, March 5	5.25	
Sunday, March 6	3	
Total hours earned (1 hour = 1 credit MOC Section 1)	15.5	

Physicians should only claim credits commensurate with the extent of their participation in the activity.

EVALUATION

Evaluate the sessions you attend and claim your CPD credits online. Evaluation stations are available in the Mali Foyer and online at <http://crs2016.ca>

How?

1. Login with the email address used during registration (If unknown, contact education@cos-soc.ca)
2. Evaluate and claim credits for the sessions you attend.
3. After evaluating all of the attended sessions, download, print or email a copy of your Certificate of attendance.
4. After March 31, 2016, login to MAINPORT to claim your credits from your holding area.

Evaluation is a required component the RCPSC's MOC program. Your feedback enables us to better understand your learning needs and plan for future educational opportunities. We appreciate the time you take to complete the evaluation for each session you attend.

GUEST SPEAKERS



K. Bailey Freund, MD

*Vitreous Retina Macula Consultants of New York
Clinical Professor of Ophthalmology, NYU School of Medicine*

K. Bailey Freund, MD, specializes in all retinal disorders including macular degeneration, diabetic retinopathy, and retinal vascular diseases and is an expert in difficult-to-diagnose and rare conditions. He has initiated and conducted many clinical trials for treatments for retinal diseases. Dr. Freund is a clinical professor of ophthalmology at New York University School of Medicine, a senior partner at Vitreous Retina Macula Consultants of New York and an attending surgeon at Manhattan Eye, Ear and Throat Hospital and New York Presbyterian Hospital. Dr. Freund is a member of the Retina Society, Macula Society, and the American Society of Retina Specialists. He is on the editorial board of the journal *Retina* and is an associate editor for *Retinal Cases & Brief Reports*. He has authored over 250 peer-reviewed scientific manuscripts and has written numerous book chapters. He has received numerous awards including the prestigious Young Investigator Award from the Macula Society. He is a graduate of Williams College and the New York University School of Medicine and completed his residency training in general ophthalmology and a fellowship in medical and surgical retina at the Manhattan Eye, Ear, and Throat Hospital. Dr. Freund is also a prominent collector of vintage magic apparatus.

Financial disclosure: I have/had an affiliation (financial or otherwise) with a commercial organization.

- | | |
|---------------------------|------------------------|
| 1. Heidelberg Engineering | 2. ThromboGeneics |
| 3. Optos | 4. Optovue |
| 5. Genentech | 6. Ohr Pharmaceuticals |



Sunir Garg, MD

*Associate Professor of Ophthalmology, The Retina Service of Wills Eye Hospital,
Thomas Jefferson University*

Dr. Sunir Garg received both his Bachelor of Science with Honors and Doctor of Medicine degrees from the University of Michigan. He also completed his residency in ophthalmology at the University of Michigan where he was appointed co-chief resident. He attended Wills Eye Hospital for his retina fellowship and became an assistant professor of ophthalmology at Washington University in St. Louis. Dr. Garg then returned to Philadelphia to join the staff of Wills Eye Hospital. Dr. Garg is board certified in Ophthalmology and is currently associate professor of ophthalmology at Sidney Kimmel Medical College at Thomas Jefferson University. Dr. Garg is a Fellow of both the American College of Surgeons and American Academy of Ophthalmology, and is an active member of the Retina Society, the Macula Society, the American Society of Retina Specialists, and the American Uveitis Society. He is president of the Greater Philadelphia Ophthalmic Society and is secretary of the Metro Philadelphia American College of Surgeons. Dr. Garg serves as principal investigator on several major national and international clinical trials, and has authored or co-authored more than 70 peer-reviewed papers, is the editor of one textbook and co-editor of two others, and has authored numerous papers and book chapters.

Financial disclosure: I have/had an affiliation (financial or otherwise) with a commercial organization.

- | | |
|------------------|--------------|
| 1. Genentech | 2. Regeneron |
| 3. Thrombogenics | 4. J&J |
| 5. Xoma | 6. Aldeyra |
| 7. Allergan | 8. Deciphera |
| 9. Santen | |

GUEST SPEAKERS



Mary Lou Jackson, MD

*Director of Vision Rehabilitation
University of British Columbia*

Dr. Mary Lou Jackson is an ophthalmologist and current director of Vision Rehabilitation at the University of British Columbia in Vancouver, BC. Prior to this, she was director of Vision Rehabilitation at the Massachusetts Eye and Ear Infirmary in the Harvard Department of Ophthalmology. She is the past chair of the American Academy of Ophthalmology Vision Rehabilitation Committee. Current research interests include Charles Bonnet Syndrome and outcomes of comprehensive vision rehabilitation.

Financial disclosure: *I have/had an affiliation (financial or otherwise) with a commercial organization.*

1. Readers Digest Partners for Sight
2. Ocata
3. Novartis
4. CNIB



Gaurav Shah, MD

*Clinical Professor of Ophthalmology and Visual Sciences
Director of Vitreoretinal Fellowship Program, The Retina Institute*

Dr. Gaurav Shah completed medical school at the University of Illinois, College of Medicine in Chicago. He traveled to Santa Clara, California for an internship at the Kaiser Permanente Medical Center, and was a resident at the University of Minnesota, Department of Ophthalmology for 3 years. He completed a 2 year fellowship at Wills Eye Hospital under the direction of Dr. William Benson. Dr. Shah came to The Retina Institute in the summer of 1999 as the Director of the Vitreo-Retinal Fellowship Program. He was voted Ophthalmology Clinical Teacher of the Year for 2001-02. Dr. Shah has published over 128 articles in ophthalmologic peer-reviewed journals, along with 10 book chapters. He has been involved in over

44 clinical trials since 1999. He has also lectured on various topics at several meetings both inside and outside the United States including Asia, South America and Europe. Dr. Shah is a faculty member with Orbis. Dr. Shah has received numerous awards, including the Heed Foundation award, Vitreous Society Honor Award and most recently, the American Academy of Ophthalmology Senior Achievement Award. He is currently an investigator in 9 clinical trials dealing with Macular Degeneration, Diabetic Retinopathy, Uveitis and AIDS.

Financial disclosure: *I do not have any affiliation (financial or otherwise) with a commercial organization.*



Alexander Walsh, MD

Dr. Alexander Walsh holds an engineering degree from Stanford University and a medical degree from the Columbia College of Physicians and Surgeons. He completed his ophthalmology residency at the Wilmer Eye Institute at Johns Hopkins Hospital and a retina fellowship at the Doheny Eye Institute at USC. He was a faculty member at Doheny and USC from 2004 until 2012 during which time his research focused on optical coherence tomography and software and hardware systems in the field of diagnostic imaging. Dr. Walsh is now a member of the Retina Vitreous Associates Medical Group in Los Angeles and runs a startup company that is building an instrument to automate the entire eye exam and provide comprehensive, affordable, accurate eye care to people around the world.

Financial disclosure: *I have/had an affiliation (financial or otherwise) with a commercial organization.*

1. Envision Diagnostics

DR. MILA OH MEMORIAL LECTURE

Saturday, March 5, 2016

1605-1700

Vision Rehabilitation for the patient receiving Intravitreal Injections

Mary Lou Jackson, MD



Mila Oh (1969-2010)

It is with great pride that we present the annual **Dr. Mila Oh Memorial Lecture**. In 1995, Mila was accepted as a resident in the Department of Ophthalmology at McGill University. From that year on, she was considered a star. She was intelligent, hardworking, and had a great sense of humour. Mila was Chief Resident in 1999 before heading to Duke University to pursue a vitreoretinal fellowship. At the Royal Victoria Hospital in Montreal she brought passion, commitment and firm opinions to the management of patients, to the training of young ophthalmologists for the betterment of her department. While battling cancer, Mila assumed the role of Interim Program Director, offering her time to relieve a colleague who was also fighting cancer.

Mila was also a key member of the COS clinical practice guidelines committee on diabetic retinopathy. The final published guidelines were dedicated to her memory. To those who were blessed to work with Mila, there was no better example of devotion, and no better example of a team player. She was a very dear friend to all and is greatly missed by her family, patients and colleagues.



Mary Lou Jackson

We are honoured to welcome Dr. Mary Lou Jackson to present this lecture.

Dr. Mary Lou Jackson is an ophthalmologist and current director of Vision Rehabilitation at the University of British Columbia in Vancouver, BC. Prior to this, she was director of Vision Rehabilitation at the Massachusetts Eye and Ear Infirmary in the Harvard Department of Ophthalmology. She is the past chair of the American Academy of Ophthalmology Vision Rehabilitation Committee. Current research interests include Charles Bonnet Syndrome and outcomes of comprehensive vision rehabilitation.

*We thank The Retina Foundation of Canada
for their generous support of this memorial lecture.*



SOCIAL EVENTS

Thursday, March 3

Welcome Reception 1900-2000

Ballroom Foyer, Mali 1&2,
Fairmont Tremblant

Start off with some joie de vivre!

Come join us in welcoming our friends and colleagues from across the country for the 2016 Canadian Retina Society Meeting, Canada's Spotlight on Retina. Beverages and light snacks will be served.

Friday, March 4

A Night at the Sugar Shack 1900-2200

Reception-style dinner (off site event – Tremblant Village Old Church)

Take in some (new) old world charm

Located in the picturesque European-style pedestrian village at the base of the mountain, Tremblant's Village Old Church is only a short 5-minute drive from the Fairmont Tremblant. Hop on our shuttle bus and enjoy an evening filled with Quebecois culture including a reception-style dinner, entertainment and even ice skating! Casual attire.

Saturday, March 5

Ice Bar Reception 1900-2000

Soutana Terrace
Fairmont Tremblant

Shaken or stirred? The choice is yours!

Come join us for a cocktail and a chat with colleagues and friends at our popular Ice Bar. The event will take place in the warm and inviting Soutana Terrace located on the terrace level of the Fairmont Tremblant.

2016 CRS MEETING LEARNING OBJECTIVES

At the end of this meeting, participants will be able to:

- Describe present and future uses of Optical Coherence Tomography;
- Identify the technological and technique-based advances in Vitreoretinal surgery;
- Describe the imaging features and therapeutic options for macular disease(s);
- Identify the evolving trends and practices of Canadian Retina Specialists in the management of retinal disease(s).

SCIENTIFIC PROGRAM

Thursday, March 3 2016 – Mali III

16:20-17:25 Scientific Session #1 – Medical Retina Case Conference

At the end of this session, participants will be able to:

- Expand your differential diagnosis for medical retinal conditions
- Identify uncommon retinal diseases
- Enhance your management of retinal diseases

1620-1625 Welcome – Jim Whelan and Netan Choudhry

1625-1725

Mystery Cases –

Panelists: Deepa Yoganathan*, K. Bailey Freund, Netan Choudhry, Jim Whelan
*Moderator

1730-1900

CRS Annual General Meeting

Join us in welcoming our friends and colleagues from across the country for the 2016 CRS Meeting, Canada's Spotlight on Retina.

1900-2000

Welcome Reception

Mali Foyer, Fairmont Tremblant

Friday, March 4 – Mali III

0600-0630 Breakfast

0630-0900 Scientific Session #2 – Retinal Imaging I

At the end of this session, participants will be able to:

- Identify recent changes to our understanding of OCT-based retinal anatomy
- Indicate key imaging features of Age-Related Macular Degeneration subtypes
- Become familiar with newer microbes implicated in culture-negative endophthalmitis

0630-0635 Welcome and Introductions –
Netan Choudhry

0635-0655 Evolving Understanding of Ocular Anatomy and Disease with OCT–
Alex Walsh

0655-0705 Q & A

0705-0725 Imaging Neovascular Subtypes in AMD –
K. Bailey Freund

0725-0735 Q & A

0735-0755 What Intravitreal Injections Have Taught Us About Endophthalmitis/First Person Recording of Retinal Procedures –
Sunir Garg

0755-0805 Panel Discussion: *Netan Choudhry**,
Sunir Garg, Alex Walsh, K. Bailey Freund
**Moderator*

0805-0855 Anti-VEGF Switch Cases - **Panelists:**
*Deepa Yoganathan**, *K. Bailey Freund,*
David E. Lederer, Rishi Gupta **Moderator*

0855-0910 Refreshment break

0910-1010 wARMD 360° – Evolution of Disease Management

Co-developed symposium*

Scientific Planning Committee:

Chair and CRS representative: *Netan Choudhry*
Members: *David E. Lederer, R. Rishi Gupta*

Faculty: *Netan Choudhry, Joan W. Miller, Rishi Gupta,*
K. Bailey Freund, David E. Lederer

At the end of this session, participants will be able to:

- Describe the evolution of treatments for exudative ARMD

- Discuss the current evidence for switching agents in the treatment of wet ARMD and non-responders.
- Assess the evidence regarding a possible association between intravitreal anti-VEGF therapy and macular atrophy in neovascular ARMD.
- Become familiar with the evolving role of OCT-angiography in the management of neovascular ARMD.

AGENDA

0910-0915 Welcome and Introductions –
Netan Choudhry

0915-0925 A Brief History of the Management of Neovascular ARMD – *R. Rishi Gupta*

0925-0935 Switching Agents: When, How, Why? –
Joan W. Miller

0935-0945 Geographic Atrophy in the Anti-VEGF Era –
K. Bailey Freund

0945-0955 New Frontiers in Retinal Imaging: OCT-Angiography for wet ARMD –
Netan Choudhry

0955-1010 Panel discussion:
Moderators: *Netan Choudhry, David E. Lederer*
Faculty: *K. Bailey Freund, R. Rishi Gupta,*
Joan W. Miller

** This session was co-developed by the CRS, the COS and Bayer and was planned to achieve scientific integrity, objectivity and balance*

1010 Adjourn

1530-1600 Refreshment break

1600-1830 Scientific Session #3 – Retinal Imaging II

At the end of this session, participants will be able to:

- Discuss future developments in Optical Coherence Tomography
- Describe the current research in retinal anatomy using Optical Coherence Tomography
- Assess the role of the choroid within the pachychoroid spectrum
- Identify imaging features of White Dot Syndromes

Friday, March 4 – Mali III

1600-1605	Introduction – <i>Jim Whelan</i>	1725-1735	Q & A
1605-1625	New Frontiers in OCT – <i>Alex Walsh</i>	1735-1800	The Pachychoroid Spectrum – <i>K. Bailey Freund</i>
1625-1635	Q & A	1800-1830	Panel Discussion: <i>Jim Whelan*</i> , <i>Alex Walsh</i> , <i>K. Bailey Freund</i> , <i>David Maberley</i> <i>*Moderator</i>
1635-1655	New Multi-Modal Imaging Findings in White Dot Syndromes – <i>K. Bailey Freund</i>	1830	Adjourn
1655-1705	Q & A	1900-2200	A Night at the Sugar Shack Old Church, Tremblant Village (offsite)
1705-1725	Automated Multi-Functional OCT – <i>Alex Walsh</i>		



CO-DEVELOPED ACCREDITED SYMPOSIUM

Friday, March 4, 2016 | 0910–1010

Canadian Retina Society
Société canadienne de la Rétine

wARMD 360° - EVOLUTION OF DISEASE MANAGEMENT

FACULTY

SCIENTIFIC PLANNING COMMITTEE

Netan Choudhry, MD, Chair and CRS representative | R. Rishi Gupta, MD | David E. Lederer, MD



Netan Choudhry, MD
Toronto, ON



K. Bailey Freund, MD
New York, NY



R. Rishi Gupta, MD
Halifax, NS



David E. Lederer, MD
Montreal, QC



Joan W. Miller, MD
Boston, MA

- 0910** Welcome and introductions – Netan Choudhry
- 0915** A brief history of the management of neovascular ARMD – R. Rishi Gupta
- 0925** Switching agents: When, how, why? – Joan W. Miller
- 0935** Geographic atrophy in the anti-VEGF era – K. Bailey Freund
- 0945** New frontiers in retinal imaging: OCT-angiography for wet ARMD – Netan Choudhry
- 0955** Panel discussion
Moderators: Netan Choudhry, David E. Lederer
Faculty: K. Bailey Freund, R. Rishi Gupta, Joan W. Miller

Light snacks and refreshments will be served

LEARNING OBJECTIVES

At the end of this session, participants will be able to:

- Describe the evolution of treatments for exudative ARMD.
- Discuss the current evidence for switching agents in the treatment of wet ARMD and non-responders.
- Assess the evidence regarding a possible association between intravitreal anti-VEGF therapy and macular atrophy in neovascular ARMD.
- Identify the evolving role of OCT-angiography in the management of neovascular ARMD.

ACCREDITATION STATEMENT This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of The Royal College of Physicians and Surgeons of Canada and approved by the Canadian Ophthalmological Society. Physicians may claim a maximum of one (1) Section 1 credit. Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association (AMA), physicians may convert Royal College MOC credits for AMA PRA Category 1 credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at <http://www.ama-assn.org> "Earning credit for participation in international activities".

Physicians should only claim credits commensurate with the extent of their participation in the activity.

This symposium was co-developed with Bayer and was planned to achieve scientific integrity, objectivity and balance.



Saturday, March 5 – Mali III

0600-0630	Breakfast
0630-0900	Scientific Session #4 – Vitreoretinal Surgery
0630-0635	Welcome and Introductions – <i>Jim Whelan</i>
0635-0700	Retinal Detachment: A Primer – <i>Gaurav Shah</i>
0700-0710	Q & A
0710-0735	27 Gauge Surgery: Applications & Limitations – <i>Gaurav Shah</i>
0735-0745	Q & A
0745-0810	Clinical Reality of Ocriplasmin Use & Outcomes – <i>Gaurav Shah</i>
0810-0820	Q & A
0820-0845	Secondary Intraocular Lenses – <i>Sunir Garg</i>
0845-0855	Panel Discussion: <i>Jim Whelan*</i> , <i>Gaurav Shah</i> , <i>Sunir Garg</i> , <i>Flavio Rezende</i> <i>*Moderator</i>
0855-0910	Refreshment break
0910-1010	Advanced VR Course: Do You Know Your Vitrectomy Machine? Things You'll Want to Know

Co-developed symposium

Scientific Planning Committee: Chair: *Wai-Ching Lam*, CRS representative: *James Whelan*, Member: *Michael Kapusta*

Faculty: *Wai-Ching Lam*, *Michael Kapusta*, *David Chow*

At the end of this session, participants will be able to:

- Describe principles and physiological rationale of the various vitrectomy parameters
- Identify the advanced settings of the vitrectomy machine
- Apply the new knowledge of the vitrectomy to achieve better patient surgical outcome

AGENDA

9:10-9:15	Welcome and Introduction – <i>Wai-Ching Lam</i>
9:15-9:25	VGFI, Flow Limit, IOP Control... Do you know what this all means? – <i>Michael Kapusta</i>

9:25-9:35	Advanced Setting of the Vitrectomy Machine: It's time to Find Out What They Are – <i>David Chow</i>
9:35-9:45	The Development of Vitreo-Retinal Surgery - Past, Present, and Future – <i>Hugh Parsons</i>
9:45-10:10	Panel Discussion: Moderator: <i>Wai-Ching Lam</i> Faculty: <i>David Chow, MD</i> , <i>Michael Kapusta</i> , <i>Hugh Parsons</i>

** This session was co-developed by the CRS, the COS and Alcon and was planned to achieve scientific integrity, objectivity and balance*

1010	Adjourn
1530-1600	Refreshment break
1600-1745	Scientific Session #5 – Vision Rehabilitation & Therapeutics
At the end of this session, participants will be able to:	
<ul style="list-style-type: none"> • Determine the retina specialists' role in vision rehabilitation • Identify emerging therapies for dry Age Related Macular Degeneration 	
1600-1605	Introductions – <i>Netan Choudhry</i> with Remarks from <i>Dr. John Galic</i> , President of The Retina Foundation of Canada
1605-1650	Dr. Mila Oh Memorial Lecture: <i>Mary Lou Jackson</i> Vision Rehabilitation for the Patient Receiving Intravitreal Injections
1650-1700	Q & A
1700-1720	Emerging Therapies for dry AMD – <i>Sunir Garg</i>
1720-1735	Panel Discussion: <i>James Whelan*</i> , <i>Sunir Garg</i> <i>*Moderator</i>
1735-1745	Foundation Fighting Blindness – Remarks by <i>Dr. Mary Sunderland</i> , Director of Research & Education
1745	Adjourn
1900-2000	Ice Bar Terrasse Soutana, Fairmont Tremblant



ADVANCED VR COURSE: DO YOU KNOW YOUR VITRECTOMY MACHINE? THINGS YOU’LL WANT TO KNOW

FACULTY



*Wai-Ching Lam, MD
Toronto, ON*



*Michael Kapusta, MD
Montreal, QC*



*David Chow, MD
Toronto, ON*



*Hugh Parsons, MD
New Westminster, BC*

SCIENTIFIC PLANNING COMMITTEE

Wai-Ching Lam, MD, Chair | James Whelan, MD, CRS Representative | Michael Kapusta, MD

- 9:10-9:15** Welcome and Introduction – Wai-Ching Lam
- 9:15-9:25** VGFI, Flow Limit, IOP Control... Do you know what this all means? – Michael Kapusta
- 9:25-9:35** Advanced settings of the vitrectomy machine: It’s time to find out what they are – David Chow
- 9:35-9:45** The development of vitreo-retinal surgery – Past, present and future – Hugh Parsons
- 9:45-10:10** Panel Discussion
Moderator: Wai-Ching Lam
Faculty: David Chow, Michael Kapusta, Hugh Parsons

Light snacks and refreshments will be served

ACCREDITATION STATEMENT This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification (MOC) Program of the Royal College of Physicians and Surgeons of Canada (RCPC) and was approved by the Canadian Ophthalmological Society. Physicians may claim a maximum of one (1) hour. Through an agreement between the RCPC and the American Medical Association (AMA), physicians may convert MOC credits for AMA PRA Category 1 credits. Information on the process to convert MOC credit to AMA credit can be found at <http://www.ama-assn.org> "Earning credit for participation in international activities".

Physicians should only claim credits commensurate with the extent of their participation in the activity.

This symposium was co-developed with Alcon and was planned to achieve scientific integrity, objectivity and balance.



LEARNING OBJECTIVES

At the end of this session, participants will be able to:

- Describe principles and physiological rational of the various vitrectomy parameters
- Identify the advanced settings of the vitrectomy machine
- Apply the new knowledge of the vitrectomy to achieve better patient surgical outcome

Sunday, March 6 – Mali III

0630-0700 Breakfast

0700-1000 Scientific Session #6 – Canadian Retina Practice Perspectives

At the end of this session, participants will be able to:

- Identify the trends in Anti-VEGF management of retinal disease in Canada
- Describe the surgical preferences and practices of Canadian vitreoretinal surgeons
- Discuss the socio-economic variability in retinal practices and coverage across Canada

0700-0705 Introduction – Jim Whelan

0705-0735 Expanding the Dialogue: Results of the Canadian Preferences and Trends (CAN-PAT) Survey – Netan Choudhry, Jim Whelan

0735-0805 Q & A

0805-0905 Challenging Surgical Cases – Panelists: Deepa Yoganathan*, Michael Kapusta, Amin Kherani
**Moderator*

0905 Adjourn

GOLD SPONSOR

Enhancing Sight. Enhancing Lives.

LEADING THE WAY IN EYE CARE

Alcon is the global leader in eye care because we are passionate about helping people see better. We are dedicated to enhancing lives by enhancing sight, one of our most precious senses. We provide patients innovative products with the goal to deliver the best patient outcomes. With our three businesses – surgical, pharmaceutical and vision care – we offer the widest spectrum of industry-leading products that address the full life cycle of eye care needs. We are proud of being a trusted partner to professionals across the globe.



Alcon[®]

a Novartis company

E
N H
A N C
I N G S
I G H T E
N H A N C I
N G L I V E S

Enhancing Sight. Enhancing Lives.
LEADING THE WAY IN EYE CARE

Alcon is the global leader in eye care because we are passionate about helping people see better. We are dedicated to enhancing lives by enhancing sight, one of our most precious senses. We provide patients innovative products with the goal to deliver the best patient outcomes. With our three businesses – surgical, pharmaceutical and vision care – we offer the widest spectrum of industry-leading products that address the full life cycle of eye care needs. We are proud of being a trusted partner to professionals across the globe.

Alcon[®]
a Novartis company

GOLD SPONSOR



Science For a Better Life — It's our promise and our commitment to all Canadians. Every day, we put science to work to improve the quality of life for people, for animals and for communities.

Our innovations in healthcare lead to breakthroughs that fight diseases and offer healthier alternatives to existing treatments. Our advances in crop science and animal health protect our food supply and improve nutrition. Our high-tech, high-performance materials improve the design and functionality of products we all use regularly.

Who is Bayer? We're Canadians, we're inventors. Together, we're making life better for everyone.

www.bayer.ca

® Bayer and Bayer Cross are registered trademarks of Bayer AG, used under licence by Bayer Inc.



Science For A Better Life



We want Canadians to live healthier, more vibrant lives. So we work tirelessly to develop better treatments and generate innovations.

Our intensive research and development efforts have yielded breakthroughs in preventing and treating cardiovascular disease, hemophilia, cancer, multiple sclerosis, bacterial and viral infections and urological disorders. And our over-the-counter medications include some of Canada's most trusted brand names.

Our dedication to finding cures, improving treatments and creating better products will never waver. Because, when Canadians live healthier lives, everybody wins.

www.bayer.ca

® Bayer and Bayer Cross are registered trademarks of Bayer AG, used under licence by Bayer Inc.



Science For A Better Life

see what we see

Allergan markets a portfolio of best-in-class products that provide valuable treatments for the eye care, central nervous system, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, providing patients around the globe with increased access to affordable, high-quality medicines.

Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry.

FOR MORE INFORMATION, VISIT THE ALLERGAN BOOTH
AND TALK TO A REPRESENTATIVE.





Each day, we have 14 billion little reminders to continue advancing eye health.

From the moment we open our eyes and start to view the possibilities of each new day, we look at how we can improve the well-being of the world's 14 billion eyes. Will this be the day when one of us unlocks a way to eliminate visual impairment in newborns? Or strikes upon a treatment that actually helps the eye heal itself? To us, these are not some distant hopes. They are the daily questions that add new urgency to all we do and everything we see for the future. We're Bausch + Lomb, a company solely focused on advancing the vision and care of the world's eyes.



Is proud to sponsor the 2016 Canadian Retina Society meeting

www.salientmed.com
Email: info@salientmed.com
Toll Free: 1.855.736.3003

We are the exclusive Canadian distributor for



Labtician Ophthalmics, Inc. is a solutions focused provider of specialty innovative medical device and pharmaceutical products to the Canadian Ophthalmic community.

Labtician provides the retinal community with reliable service and high quality products from our exclusive commercial partners including Fluoron, Ophthalmic Direct and Beaver-Visitec International, Inc.

Our long time alliance with Fluoron provides us the opportunity to introduce New Generation Silicone Oils, Siluron 2000 and Xtra. The re-engineering of these oils has increased their emulsification resistance demonstrating exceptional long term tolerance and improved surgical handling through today's small gauge set-up while maintaining the chemical substance and purity that has been clinically proven for over 50 years.

Ophthalmic Direct's service is underpinned by GMD's strengths in cold chain distribution, customer service, and stakeholder management.

Ophthalmic Direct offers a unique direct distribution channel for specialty ophthalmic products via our partnering network of ophthalmology clinics across Canada.

Through our direct distribution model we ship products directly to ophthalmologist's offices where we also set up and manage the infrastructure required for proper storage and handling.

Ophthalmic Direct fosters close working relationships with all stakeholders in the process, thereby allowing for seamless care. Our team of dedicated specialists ensures that product supplies are available at clinics when they are needed and also help patients navigate the often cumbersome insurance process needed to obtain coverage.

Our growing presence in Canada positions us uniquely to help our clients to put their product directly into the hands of leading ophthalmologists across the country.

Cleon Strouthos
Tel: 905-829-0055
email - cstrouthos@labtician.com
www.labtician.com

Sally Bibic
Tel: 289-242-8238
email - sbibic@ophthalmicdirect.ca
www.ophthalmicdirect.ca



Novartis Pharmaceuticals Canada

Novartis Pharmaceuticals Canada Inc., a leader in the healthcare field, is committed to the discovery, development and marketing of innovative products to improve the well-being of all Canadians. Novartis Pharmaceuticals Canada Inc. employs more than 700 people in Canada. For further information, please consult www.novartis.ca.

Located in Dorval, Quebec, Novartis Pharmaceuticals Canada Inc. is an affiliate of Novartis AG, which provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet

these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2014, the Group achieved net sales of USD 58.0 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 120,000 full-time equivalent associates. Novartis products are available in more than 180 countries around the world. For more information, please visit <http://www.novartis.com>.



www.novartis.ca

MEDICAL PHARMACIES



Medical Pharmacies Group Limited (MPGL) and its wholly owned subsidiary, OMS, are proud to be a corporate sponsor of this year's Canadian Retina Society Meeting.

As a leading Canadian provider of specialty pharmacy and healthcare products and services, our core focus is on supporting patients and healthcare providers across all care settings to achieve optimal health outcomes.

Medical Pharmacies' Specialty division provides customized pharmacy and patient support services that enhance Ophthalmology practice efficiency, patient convenience and safety. Our Med-e-Consult Patient Assistance and Specialty Pharmacy teams work closely with specialists' offices, administration clinics, hospitals, long term care institutions and other stakeholders to simplify the ordering, delivery, administration and reimbursement of specialized ophthalmic treatments and other specialty drug therapies treating a wide range of chronic conditions.

Services include:

- Specialty Pharmacy Support
- Infusion and Injectable Therapy Preparation
- Medical Supplies, Procedure Kits, Equipment
- Med-e-Consult Patient Assistance Services
- Clinic Administration and Support
- Institutional Pharmacy Services
- Cold Chain Pharmaceutical Logistics & Inventory Management



Call us today to learn more about Medical Pharmacies' Specialty Services
1-855-710-8499 • medicalpharmacies.com/specialty-pharmacy



YOU CAN RESTORE HOPE & SIGHT



Join the fight against blindness at ffb.ca



The FOUNDATION
FIGHTING BLINDNESS

EMERGENT AND EMERGING CARE



SOINS URGENTS ET THÉRAPIES INNOVANTES

**ANNUAL MEETING
& EXHIBITION**

**CONGRÈS ANNUEL
ET EXPOSITION**



Canadian Ophthalmological Society
canadienne d'ophtalmologie
SOCIÉTÉ D'OPHTALMOLOGISTES
ET CHIRURGIENS DU CANADA

2016

OTTAWA

JUNE 17-20 JUNI, 2016
SHAW CENTRE / OTTAWA, ONTARIO, CANADA

cos-sco.ca/ottawa2016



The CRS welcomes you to join us at the 79th COS Annual Meeting and Exhibition, taking place at the Shaw Centre in Ottawa, Ontario June 17-20, 2016.

This year's educational program will focus on emergent and emerging care in ophthalmology including cutting-edge surgical innovations, state-of-the-art advances in diagnostics and evidence-based updates. At the COS meeting, Canadian retina experts will have a unique opportunity to learn from 18 renowned international guest speakers including well-known retina specialists, Dr. Jay S. Duker (2016 Canadian Journal of Ophthalmology Speaker) and Dr. Carl Regillo.

We look forward to seeing you in June in our Nation's Capital!



Dr. Jay S. Duker



Dr. Carl Regillo



WHISTLER 2017

Canadian Retina Society Meeting

Join us next year in Whistler, BC as we return to North America's finest mountain resort for the 2017 CRS Meeting, the largest gathering of retina specialists in Canada.



PROGRAM AT A GLANCE

2016 CRS MEETING LEARNING OBJECTIVES

At the end of this meeting, participants will be able to:

- Describe present and future uses of Optical Coherence Tomography;
- Identify the technological and technique-based advances in Vitreoretinal surgery;
- Describe the imaging features and therapeutic options for macular disease(s);
- Identify the evolving trends and practices of Canadian Retina Specialists in the management of retinal disease(s).

Thursday, March 3 2016

16:20-17:25 Scientific Session #1 – Medical Retina Case Conference

1620-1725 Mystery cases – **Panelists:** Deepa Yoganathan, K. Bailey Freund, Netan Choudhry, Jim Whelan

1730-1900 CRS Annual General Meeting

1900-2000 Welcome Reception
Mali Foyer, Fairmont Tremblant

Friday, March 4 2016

0600-0630 Breakfast

0630-0900 Scientific Session #2 – Retinal Imaging I
Evolving Understanding of Ocular Anatomy and Disease with OCT – Alex Walsh
Imaging Neovascular Subtypes in AMD – K. Bailey Freund
What intravitreal injections have taught us about endophthalmitis/First person recording of retinal procedures – Sunir Garg
Anti-VEGF switch cases – **Panelists:** Deepa Yoganathan, K. Bailey Freund, David E. Lederer, Rishi Gupta

0855-0910 Refreshment break

0910-1010 wARMD 360° - Evolution of Disease Management
Co-developed symposium*

Faculty: Netan Choudhry, Joan W. Miller, Rishi Gupta, K. Bailey Freund, David E. Lederer

** This session was co-developed by the Canadian Retina Society, the Canadian Ophthalmological Society and Bayer and was planned to achieve scientific integrity, objectivity and balance*

1530-1600 Refreshment break

1600-1830 Scientific Session #3 – Retinal Imaging II
New Frontiers in OCT – Alex Walsh
New Multi-Modal Imaging Findings in White Dot Syndromes – K. Bailey Freund
Automated Multi-Functional OCT – Alex Walsh
The Pachychoroid Spectrum – K. Bailey Freund

1900-2200 A Night at the Sugar Shack
Reception-style dinner – The Old Church, Tremblant Village (offsite)

Saturday, March 5 2016

0600-0630 Breakfast

0630-0900 Scientific Session #4 – Vitreoretinal Surgery
Retinal Detachment: A Primer – Gaurav Shah
27 Gauge Surgery: Applications & Limitations – Gaurav Shah
Clinical Reality of Ocriplasmin Use & Outcomes – Gaurav Shah
Secondary Intraocular lenses – Sunir Garg

0855-0910 Refreshment break

0910-1010 Advanced VR Course: Do you know your vitrectomy machine? Things you'll want to know

Co-developed symposium*

Faculty: Wai-Ching Lam, James Whelan, Michael Kapusta, David Chow

** This session was co-developed by the Canadian Retina Society, the Canadian Ophthalmological Society and Alcon and was planned to achieve scientific integrity, objectivity and balance*

1530-1600 Refreshment break

1600-1745 Scientific Session #5 – Vision Rehabilitation & Therapeutics
Dr. Mila Oh Memorial Lecture - Remarks by Dr. John Galic, President of The Retina Foundation of Canada - Vision Rehabilitation for the Patient Receiving Intravitreal Injections - Mary Lou Jackson
Emerging therapies for dry AMD – Sunir Garg
Foundation Fighting Blindness – Remarks by Dr. Mary Sunderland, Director of Research & Education

1900-2000 Ice Bar Reception
Soutana Terrace, Fairmont Tremblant

Sunday, March 6, 2016

0630-0700 Breakfast

0700-1000 Scientific Session #6 – Canadian Retina Practice Perspectives
Expanding the Dialogue: Results of the Canadian Preferences and Trends (CAN-PAT) Survey – Netan Choudhry, Jim Whelan
Challenging surgical cases – **Panelists:** Deepa Yoganathan, Michael Kapusta, Amin Kherani